Illumina Acquires Fluent BioSciences
July 9, 2024
Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.
- Buyers
- Illumina, Inc.
- Targets
- Fluent BioSciences
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Cell Microsystems Acquires Fluxion Biosciences
August 23, 2023
Medical Devices
Durham-based Cell Microsystems has acquired Fluxion Biosciences, adding Fluxion's IonFlux, BioFlux and IsoFlux instruments and services to its CellRaft-based product portfolio. The deal is supported by a concurrent Series B financing led by Telegraph Hill Partners to provide growth capital and accelerate product and service integration for cellular analysis and electrophysiology workflows.
-
Anaplan Acquires Fluence Technologies
April 26, 2024
Cloud & SaaS
Anaplan has entered into a definitive agreement to acquire Fluence Technologies, a Toronto-based provider of cloud-native financial close, consolidation, disclosure management and Excel reporting software. The acquisition (expected to close in early May) will integrate Fluence’s consolidation and disclosure capabilities into Anaplan’s connected planning platform to strengthen CFO-focused functionality and reduce system and process complexity. Integration will be led by Anaplan’s product leaders alongside Fluence product leadership.
-
Integrated DNA Technologies Acquires Swift Biosciences
March 11, 2021
Biotechnology
Integrated DNA Technologies (IDT) has acquired Swift Biosciences, a developer of Next-Generation Sequencing (NGS) library preparation and enrichment kits. The acquisition brings Swift's library prep and enrichment portfolio and Ann Arbor-based team into IDT to expand IDT's NGS product offerings and accelerate growth in academic, translational, and clinical research markets. Financial terms were not disclosed.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
-
Bionano Genomics Acquires BioDiscovery
October 12, 2021
Software
Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.
-
Fulgent Genetics Acquires Fulgent Pharma
November 7, 2022
Biotechnology
Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.